

Vijay M Patil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6076293/publications.pdf>

Version: 2024-02-01

72
papers

516
citations

840776

11
h-index

794594

19
g-index

73
all docs

73
docs citations

73
times ranked

772
citing authors

#	ARTICLE	IF	CITATIONS
1	Tackling brain metastases from lung cancer during the COVID-19 pandemic. <i>Cancer Reports</i> , 2022, 5, e1276.	1.4	4
2	Systemic Therapy in Thyroid Cancer. <i>Indian Journal of Surgical Oncology</i> , 2022, 13, 68-80.	0.7	1
3	Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes. <i>Oral Oncology</i> , 2022, 125, 105709.	1.5	0
4	Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study. <i>Journal of Neuro-Oncology</i> , 2022, 156, 625-634.	2.9	2
5	Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 272-281.	1.6	22
6	Prognostic impact of semantic MRI features on survival outcomes in molecularly subtyped medulloblastoma. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 291.	2.0	1
7	Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes. <i>Radiotherapy and Oncology</i> , 2022, 170, 151-158.	0.6	5
8	Optimizing Postoperative Adjuvant Therapy in Elderly Patients with Newly Diagnosed Glioblastoma: Single-Institution Audit of Clinical Outcomes from a Tertiary-Care Comprehensive Cancer Center in India. <i>World Neurosurgery</i> , 2022, , .	1.3	1
9	Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers. <i>Oral Oncology</i> , 2022, 127, 105824.	1.5	2
10	RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation. <i>Oral Oncology</i> , 2022, 128, 105816.	1.5	2
11	Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2022, 9, 354-363.	1.6	3
12	MEDB-27. Clinico-Radiological Outcomes in WNT-pathway Medulloblastoma: Retrospective Single Institutional Audit. <i>Neuro-Oncology</i> , 2022, 24, i110-i111.	1.2	0
13	Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer. <i>JCO Global Oncology</i> , 2022, , .	1.8	10
14	Oral metronomic therapy in head and neck cancer – Authors' reply. <i>The Lancet Global Health</i> , 2021, 9, e21.	6.3	0
15	Safety and efficacy of concurrent carboplatin during full-dose craniospinal irradiation for high-risk/metastatic medulloblastoma in a resource-limited setting. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28925.	1.5	6
16	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer. <i>BMJ Open</i> , 2021, 11, e041345.	1.9	3
17	Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 15 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e043628.	1.9	6
18	Intensity-modulated radiation therapy for nasal cavity and paranasal sinus tumors: Experience from a single institute. <i>Head and Neck</i> , 2021, 43, 2045-2057.	2.0	4

#	ARTICLE	IF	CITATIONS
19	Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations. <i>Oncotarget</i> , 2021, 12, 578-588.	1.8	13
20	Distress Screening in Head and Neck Cancer Patients Planned for Cancerâ€Directed Radiotherapy. <i>Laryngoscope</i> , 2021, 131, 2023-2029.	2.0	6
21	Adolescentâ€adult nonmetastatic Ewing sarcomaâ€Experience from a large developing country. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29081.	1.5	3
22	Advances in pharmacotherapy for head and neck cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2007-2018.	1.8	5
23	Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study. <i>Cancer Medicine</i> , 2021, 10, 6725-6735.	2.8	4
24	Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. <i>World Neurosurgery</i> , 2021, 154, e176-e184.	1.3	1
25	Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone â€Additional data from a phase 3 trial. <i>Oral Oncology</i> , 2021, 122, 105517.	1.5	10
26	Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862199128.	2.4	1
27	A realâ€world data of Immune checkpoint inhibitors in solid tumors from India. <i>Cancer Medicine</i> , 2021, 10, 1525-1534.	2.8	17
28	Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC). <i>Ecancermedicalsecience</i> , 2021, 15, 1325.	1.1	4
29	Prognostic Impact of Pattern of Mandibular Involvement in Gingivo-Buccal Complex Squamous Cell Carcinomas: Marrow and Mandibular Canal Staging System. <i>Frontiers in Oncology</i> , 2021, 11, 752018.	2.8	10
30	Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis. <i>Oral Oncology</i> , 2020, 100, 104455.	1.5	9
31	Differentiating dural metastases from meningioma: role of 68Ga DOTA-NOC PET/CT. <i>Nuclear Medicine Communications</i> , 2020, 41, 356-362.	1.1	16
32	Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?. <i>Neuro-Oncology</i> , 2020, 22, 1887-1888.	1.2	4
33	Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of nonâ€small cell lung cancer (NSCLC) with brain metastases. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1427-1436.	1.9	5
34	Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 405-415.	2.9	9
35	An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breastâ€ovarian cancer syndrome. <i>South Asian Journal of Cancer</i> , 2020, 09, 06-12.	0.6	6
36	Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations. <i>Indian Journal of Cancer</i> , 2020, 57, 18.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience. South Asian Journal of Cancer, 2020, 09, 180-182.	0.6	1
38	Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping. Journal of Neuro-Oncology, 2019, 144, 283-291.	2.9	28
39	Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. EClinicalMedicine, 2019, 9, 19-25.	7.1	6
40	<p>Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 1-10.	2.7	29
41	An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma. South Asian Journal of Cancer, 2019, 08, 159-165.	0.6	1
42	Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid. South Asian Journal of Cancer, 2019, 08, 185-188.	0.6	1
43	Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience. South Asian Journal of Cancer, 2019, 08, 211-225.	0.6	1
44	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. Oncotarget, 2019, 10, 6297-6307.	1.8	1
45	Metastatic Renal Cell Cancerâ€™Systemic Therapy. Indian Journal of Surgical Oncology, 2018, 9, 97-104.	0.7	2
46	Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study. Ecancermedalscience, 2018, 12, 876.	1.1	5
47	Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell, 2018, 34, 792-806.e5.	16.8	102
48	Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. Lung India, 2018, 35, 27.	0.7	3
49	Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer. South Asian Journal of Cancer, 2018, 07, 194-202.	0.6	1
50	Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. South Asian Journal of Cancer, 2018, 07, 249-252.	0.6	8
51	Outcomes with Palliative Weekly Paclitaxel in Advanced, Recurrent, and Metastatic Esophageal Cancer -â€™Real World Experience. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 46-51.	0.2	0
52	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.2	0
53	Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience.. Journal of Clinical Oncology, 2018, 36, e15065-e15065.	1.6	1
54	Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Nonâ€™Small-Cell Lung Cancer. Journal of Global Oncology, 2017, 3, 208-217.	0.5	33

#	ARTICLE	IF	CITATIONS
55	P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC. Journal of Thoracic Oncology, 2017, 12, S1223.	1.1	1
56	Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer. Oral Oncology, 2017, 75, 54-60.	1.5	11
57	Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test. Asian Journal of Oncology, 2017, 03, 039-044.	0.2	3
58	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?. Chemotherapy Research and Practice, 2017, 2017, 1-4.	1.6	1
59	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed+carboplatin chemotherapy. Ecanermedscience, 2017, 11, 776.	1.1	2
60	Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline. Journal of Global Oncology, 2017, 3, 346-359.	0.5	3
61	Role of neoadjuvant chemotherapy in advanced carcinoma of the hypopharynx and larynx. South Asian Journal of Cancer, 2017, 06, 015-019.	0.6	7
62	Demographic profile, clinicopathological spectrum, and treatment outcomes of primary central nervous system tumors: Retrospective audit from an academic neuro-oncology unit. Indian Journal of Cancer, 2017, 54, 594.	0.2	5
63	Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer. South Asian Journal of Cancer, 2017, 06, 143-146.	0.6	4
64	Taxane combination chemotherapy in breast cancer: Experience from a tertiary cancer centre in India. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 18.	0.2	2
65	Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 311.	0.2	0
66	Next generation metronomic chemotherapy report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. Ecanermedscience, 2016, 10, 689.	1.1	10
67	Expectations and preferences for palliative chemotherapy in head and neck cancers patients. Oral Oncology, 2016, 63, 10-15.	1.5	16
68	Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer. IDCases, 2016, 3, 8-9.	0.9	0
69	Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. Supportive Care in Cancer, 2016, 24, 1595-1602.	2.2	14
70	Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 132-132.	0.2	0
71	Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 172-175.	0.2	3
72	Metronomic chemotherapy in advanced oral cancers. Journal of Cancer Research and Therapeutics, 2012, 8, 106.	0.9	16